secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2026-05-18T20:15:33+00:00
Accession:  0001104659-26-063202
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar director Loren not standing for reelection; Nantahala analyst Gu appointed to board
--------------------------------------------------------------------------------

- Dr. Stefan Loren will not stand for reelection at 2026 annual meeting; no disagreement with the company.
- Loren enters consulting agreement: $15,000/quarter for one year, plus 15,000 stock option grant.
- Andrew Gu appointed as Class III director on May 18, 2026, selected by Nantahala Capital Management.
- Gu is an analyst at Nantahala, focuses on biotech; he joins the Audit Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465926063202/0001104659-26-063202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465926063202/tm2614924d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-063202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer